Expression of MDR1, HIF-1α and MRP1 in sacral chordoma and chordoma cell line CM-319
نویسندگان
چکیده
BACKGROUND Chordoma was a typically slow-growing tumor. The therapeutic approach to chordoma had traditionally relied mainly on surgical therapy. And the main reason for therapeutic failure was resistance to chemotherapy and radiotherapy. However the refractory mechanism was not clear. The aim of this study was to investigate the expression of three genes (MDR1, HIF-1α and MRP1) associated with resistance to chemotherapy and radiotherapy in chordoma and chordoma cell line CM-319. MATERIALS AND METHODS Using immunohistochemical techniques, the expression of MDR1, HIF-1α and MRP1 was investigated in 50 chordoma specimen. Using RT-PCR and Western blot, the expression of MDR1, HIF-1α and MRP1 was investigated in chordoma and chordoma cell line CM-319. RESULTS Expression of MDR1, HIF-1α and MRP1 was observed in 10%, 80% and 74% of all cases, respectively. Expression of MRP1 was correlated with HIF-1α. On the other hand, expression of MDR1 was not correlated with the expression of HIF-1α or MRP1. The expression of HIF-1α and MRP1 was observed, but MDR1 was not observed in chordoma and CM-319. CONCLUSION Expression of HIF-1α and MRP1 was observed in most chordoma specimen and CM-319 cell line; expression of HIF-1α correlated with MRP1. HIF-1α and MRP1 may play a role in the multidrug resistance of chordoma to chemotherapy.
منابع مشابه
Cutaneous Metastasis from Sacral Chordoma: A Case Report
Chordoma is a malignant, slow growing and locally aggressive tumor. It arises from remnants of the notochord and accounts for 1–4% of all primary bone tumors. They usually arise from anywhere along the spine, from base of the skull to the sacrococcygeal area and usually do not metastasize. Chordomas are slow-growing tumors which are not responsive to conventional chemotherapy or radiation. They...
متن کاملLow expression of PHLPP1 in sacral chordoma and its association with poor prognosis.
Sacral chordoma is a rare spine tumor with a high recurrence rate even after optimal therapy. Previous studies have demonstrated that the PI3K/AKT pathway plays a pivotal role in chordoma, and high expression of pAKT is associated with poor prognosis. Recently, PHLPP was recognized to be a tumor suppressor that targets AKT. We analyzed the expression of PHLPP1 and AKT2 in 37 chordoma samples an...
متن کاملMolecular profiling of chordoma
The molecular basis of chordoma is still poorly understood, particularly with respect to differentially expressed genes involved in the primary origin of chordoma. In this study, therefore, we compared the transcriptional expression profile of one sacral chordoma recurrence, two chordoma cell lines (U-CH1 and U-CH2) and one chondrosarcoma cell line (U-CS2) with vertebral disc using a high-densi...
متن کاملAberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas.
PURPOSE Chordomas are rare, malignant bone neoplasms in which the pathogenic mechanisms remain unknown. Interestingly, tuberous sclerosis complex (TSC) is the only syndrome in which the incidence of chordomas has been described. We previously reported the pathogenic role of the TSC genes in TSC-associated chordomas. In this study, we investigated whether aberrant TSC/mammalian target of rapamyc...
متن کاملAssociation of telomerase expression with recurrence of sacral chordoma.
Originated from the remnants of the notochord in the process of fetal development, chordoma is a rare, slow growing and locally invasive low-grade malignant tumor with an annual incidence rate of 1/8 000 000 [1]. There are no standard prognostic markers in this disease. This retrospective study assessed telomerase in 20 patients of sacral chordoma (10 males and 10 females, aged 18–77 years). Th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 29 شماره
صفحات -
تاریخ انتشار 2010